PBS Biotech, under the visionary leadership of Brian Lee, Ph.D., is revolutionizing the cell therapy landscape. Specializing in scalable, single-use bioreactor solutions, PBS Biotech empowers scientists and healthcare innovators with state-of-the-art technologies for cell therapy development and commercialization. The company’s advanced products, from the PBS-0.1 Mini Vertical-Wheel Bioreactor to the high-capacity PBS-80 model, are designed to optimize cell cultures for a wide range of therapeutic applications, including cancer, diabetes, and heart failure. With a mission to advance therapeutic cell manufacturing, PBS Biotech leverages the vertical-wheel mixing technology, ensuring consistent, scalable, and predictable results from lab-scale to commercial production. Its products and services enable the creation of life-saving treatments, designed to meet the stringent regulatory standards for clinical trials and beyond.

PBS Biotech’s flagship technology—the Vertical-Wheel Bioreactor—has proven to be a game-changer in the field of cell therapy manufacturing. The Vertical-Wheel impeller’s unique design creates an optimal mixing environment for anchorage-dependent human cells. Unlike traditional bioreactors, the vertical-wheel approach minimizes shear stress, ensures consistent particle suspension, and promotes uniform energy dissipation rates (EDR), all crucial factors for producing high-quality therapeutic cells. Whether working with induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), or CAR-T cells, PBS Biotech’s bioreactors enable scalable and reproducible cell culture processes. The result is a more efficient, cost-effective path to the production of cell therapies, whether in early research phases or in commercial-scale production. As cell therapy research continues to expand, PBS Biotech is continuously innovating, designing bioreactors that are compatible with increasingly complex and larger-scale therapeutic needs. From the PBS-0.1 Mini Bioreactor, ideal for optimizing small sample volumes, to the massive PBS-80 Bioreactor, designed for large-scale clinical and commercial manufacturing, PBS Biotech’s offerings serve as the backbone for the next generation of cell therapies. These bioreactors support various advanced research and therapeutic domains, such as immune-oncology, regenerative medicine, and gene therapies, showcasing PBS Biotech’s versatility in a rapidly evolving market.

Scalability and Regulatory Compliance: Cornerstones of PBS Biotech’s Success

One of the critical challenges facing the cell therapy industry is the ability to scale cell production from small laboratory settings to larger, commercial-scale operations. PBS Biotech addresses this challenge with a robust range of bioreactor models, from 0.1L to 80L, all designed to offer scalable solutions without compromising on performance. In addition to scalability, PBS Biotech ensures that all its products comply with the highest regulatory standards. Its bioreactors are made with materials that meet the rigorous requirements for first-in-human clinical trials, ensuring that its clients can seamlessly transition from research and development to clinical and commercial stages. PBS Biotech’s commitment to quality and compliance extends to its BioLab, a state-of-the-art facility where process development is carried out. This lab is home to scientists and engineers who collaborate closely with clients to tailor scalable processes specific to their cell therapy products. By leveraging the latest in bioprocessing technology and expertise, PBS Biotech has helped clients achieve key milestones, such as successful navigation of first-in-human trials. The BioLab also enables the fine-tuning of bioreactor operations to ensure maximum productivity, improving the efficiency and cost-effectiveness of cell therapy production.

A Vision for the Future: Driving Innovation in Cell Therapy Manufacturing

Looking ahead, PBS Biotech remains committed to driving innovation in the bioreactor space. The company continues to develop new products that not only address current market needs but anticipate the future demands of cell therapy manufacturers. Whether it’s through enhancing bioreactor scalability, improving cell culture conditions, or expanding its product portfolio to include advanced features like integrated sensors and enhanced data analytics, PBS Biotech is poised to remain a leader in the biotechnological landscape. Dr. Lee’s vision for PBS Biotech is clear: to provide scalable, reliable, and high-quality tools that will enable the widespread use of cell therapies in treating some of the world’s most devastating diseases. The company is also exploring new technologies and expanding its product line, ensuring that it stays ahead of the curve as the cell therapy industry evolves. As new therapeutic modalities emerge, such as CRISPR-based gene editing and personalized medicine, PBS Biotech is well-positioned to provide the bioreactor solutions needed to manufacture these groundbreaking treatments at scale.

An Experienced Partner for Cell Therapy Success

As a trusted partner for companies working on the next wave of medical innovations, PBS Biotech’s approach is rooted in a deep understanding of both the science and the business of cell therapy. The company not only provides top-of-the-line bioreactors but also works hand-in-hand with customers to optimize their cell culture processes, ensuring that these therapies can be produced at the scale required for commercial success. With a team of experts ready to support each client’s unique needs, PBS Biotech has become synonymous with excellence in cell therapy manufacturing. From the development of cutting-edge bioreactors to assisting with regulatory approvals, PBS Biotech has become a vital ally to businesses looking to bring life-saving therapies to market. The company’s client-centric approach helps foster long-term relationships, making PBS Biotech a go-to partner for those aiming to scale their therapeutic solutions effectively.

A Lasting Impact on the Biotech Industry

In an industry that is evolving at an unprecedented rate, PBS Biotech has emerged as a key player in accelerating the commercialization of cell therapies. Through its commitment to quality, scalability, and innovation, the company has laid the foundation for a future where cell therapies are not only feasible but accessible to those who need them most. Dr. Lee’s leadership has been the driving force behind this success. His forward-thinking approach to biotechnology, combined with PBS Biotech’s cutting-edge products, positions the company at the forefront of the rapidly growing cell therapy sector. The company’s ability to anticipate market needs and continuously evolve its product offerings, while adhering to the highest regulatory standards, underscores its role as a critical enabler of cell therapy breakthroughs. As the industry matures and demand for scalable, cost-effective manufacturing solutions intensifies, PBS Biotech’s bioreactors will remain a cornerstone of innovation in the field, shaping the future of biotechnology.

Brian Lee, Ph.D., CEO and Founder

"At PBS Biotech, we’re not just creating products; we’re building the future of medicine. By enabling scalable, reliable, and high-quality cell therapy production, we are helping to bring life-saving treatments to those who need those most."